Neuroprotective Products: World Market Prospects 2012-2022
Your guide to trends and revenue prospects in neuroprotection
What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks.
Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022.
The protection of nerve tissues is becoming more important. You can assess the potential for drug revenues there, as well as finding discussions of stem cells and gene therapy.
In particular, how will 11 products - including Rasagiline, Minocycline, Memantine and NeuroSTAT - perform to 2022? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of five world-level submarkets to 2022, finding potential revenues:
Our study lets you assess the R&D pipeline, seeing trends and prospects. You find data and discussions on developmental topics:
The neuroprotection market offers strong opportunities for medicines to slow disease progression, protecting the central nervous system (CNS). Our report shows and explains.
Market value for 2014 and outlook for the future
What does the future hold? The pharma industry will develop more drugs for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising. Overall world revenues will reach $2.6bn in 2014, our report forecasts.
We predict that the neuroprotection market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and products will gain regulatory approval. You see prospects for novel drugs.
Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Also stimulating the industry and market will be the treatment of brain injuries, especially those from traffic accidents.
What are companies doing? Our work discusses Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and others, evaluating commercial prospects. The scope of the field is widening, with many organisations entering and collaborating.
The aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). However, not all neuroprotective agents will be neuroregenerative, the study predicts.
Regulatory agencies recognise the therapeutic potential of neuroprotective agents and have given fast track designation and orphan drug status to candidates.
You can investigate the future of neuroprotection now, discovering revenue potential and other prospects.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 46 tables, 22 charts and two research interviews.
Nine ways Neuroprotective Products: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for neuroprotective treatments
Our study is for everybody needing industry and market analyses for neuroprotection. You find data, predictions and answers there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks.
Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022.
The protection of nerve tissues is becoming more important. You can assess the potential for drug revenues there, as well as finding discussions of stem cells and gene therapy.
In particular, how will 11 products - including Rasagiline, Minocycline, Memantine and NeuroSTAT - perform to 2022? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of five world-level submarkets to 2022, finding potential revenues:
- Ion channel modulators
- Mitochondrial dysfunction regulators
- Anti-inflammatory and anti-apoptotic agents
- Neurotrophic factors
- Other neuroprotective treatments.
Our study lets you assess the R&D pipeline, seeing trends and prospects. You find data and discussions on developmental topics:
- Alzheimer's disease
- Parkinson's disease
- Multiple sclerosis
- Brain injury
- Ocular degeneration (retinal disorders)
- Huntington's disease
- Amyotrophic lateral sclerosis (ALS)
- Neuropathies
- Other disorders affecting the nervous system.
The neuroprotection market offers strong opportunities for medicines to slow disease progression, protecting the central nervous system (CNS). Our report shows and explains.
Market value for 2014 and outlook for the future
What does the future hold? The pharma industry will develop more drugs for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising. Overall world revenues will reach $2.6bn in 2014, our report forecasts.
We predict that the neuroprotection market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and products will gain regulatory approval. You see prospects for novel drugs.
Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Also stimulating the industry and market will be the treatment of brain injuries, especially those from traffic accidents.
What are companies doing? Our work discusses Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and others, evaluating commercial prospects. The scope of the field is widening, with many organisations entering and collaborating.
The aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). However, not all neuroprotective agents will be neuroregenerative, the study predicts.
Regulatory agencies recognise the therapeutic potential of neuroprotective agents and have given fast track designation and orphan drug status to candidates.
You can investigate the future of neuroprotection now, discovering revenue potential and other prospects.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 46 tables, 22 charts and two research interviews.
Nine ways Neuroprotective Products: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
- Find potential revenues to 2022 for the world market and submarkets
- Discover projected revenue trends of 11 leading products to 2022
- See predictions of launch times for prominent drug candidates
- Assess 7 leading companies, and other players, discovering activities and outlooks
- Review R&D pipelines, seeing trends by therapeutic area and organisation
- Investigate competition and opportunities influencing sales
- Find out what will stimulate and restrain the industry and market
- Analyse prospects for established companies and those seeking to enter the sector
- View opinions from our survey, seeing interviews with authorities in industry.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for neuroprotective treatments
Our study is for everybody needing industry and market analyses for neuroprotection. You find data, predictions and answers there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. EXECUTIVE SUMMARY
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Scope of the Report
1.4.1 Inclusions
1.4.2 Exclusions
2. INTRODUCTION TO NEUROPROTECTION
2.1 What is Neuroprotection?
2.2 History of Neuroprotective Agents
2.3 Neurodegeneration
2.3.1 Excitotoxicity
2.3.2 Oxidative Stress
2.4 Mechanisms of Neuroprotection
2.4.1 Ion Channel Modulators
2.4.2 Mitochondrial Dysfunction Regulators
2.4.3 Anti-inflammatory and Anti-apoptotic Agents
2.4.4 Neurotrophic Factors
2.4.5 Other Neuroprotective Agents
2.5 Importance of Neuroprotective Agents
3. WORLD MARKET FOR NEUROPROTECTIVE AGENTS TO 2022
3.1 Neuroprotective Agents: World Market, 2011
3.2 Neuroprotective Agents: World Market Forecast, 2012-2022
3.3 Classes of Neuroprotective Agent
3.3.1 Ion Channel Modulators
3.3.1.1 Ion Channel Modulators: Market Forecast, 2011-2012
3.3.2 Mitochondrial Dysfunction Regulators
3.3.2.1 Mitochondrial Dysfunction Regulators: Market Forecast, 2012-2022
3.3.3 Anti-inflammatory and Anti-apoptotic Agents
3.3.3.1 Anti-inflammatory and Anti-apoptotic Agents: Market Forecast, 2012-2022
3.3.4 Neurotrophic Factors
3.3.4.1 Neurotrophic Factors: Market Forecast, 2012-2022
3.3.5 Other Neuroprotective Agents
3.3.5.1 Other Neuroprotective Agents: Market Forecast, 2012-2022
4. PROMINENT NEUROPROTECTIVE AGENTS UNDER DEVELOPMENT
4.1 Rasagiline (Teva/Lundbeck)
4.1.1 Rasagiline is Currently Approved for Parkinson's Disease
4.1.2 Rasagiline as a Neuroprotectant
4.1.3 Rasagiline: Market Potential Analysis, 2012-2022
4.1.4 Competition for Rasagiline
4.2 Minocycline (National Institute of Neurological Disorders and Stroke [NINDS])
4.2.1 Minocycline: Competitor Analysis and Sales Forecast, 2012-2022
4.3 Memantine (Merz/Lundbeck/Forest Laboratories/Daiichi Sankyo)
4.3.1 Memantine: Competitor Analysis and Sales Forecast, 2012-2022
4.4 NeuroSTAT (NeuroVive Pharmaceutical AB)
4.4.1 NeuroSTAT: Competitor Analysis and Sales Forecast, 2012-2022
4.5 Erythropoietin (Various Companies)
4.5.1 EPO: Competitor Analysis and Sales Forecast, 2012-2022
4.6 GM6 (Genervon Biopharmaceuticals)
4.6.1 Current Status of Development
4.6.2 GM6 Sales Forecast, 2012-2022
4.6.3 GM6: Competitors and Risk Analysis
4.7 NNZ-2566 (Neuren Pharmaceuticals)
4.7.1 NNZ-2566: Competitor Analysis and Sales Forecast, 2012-2022
4.8 Progesterone (BHR-100, BHR Pharma LLC)
4.8.1 Progesterone: Competitor Analysis and Sales Forecast, 2012-2022
4.9 Davunetide (Allon Therapeutics)
4.9.1 Davunetide: Competitor Analysis and Sales Forecast, 2012-2022
4.10 Laquinimod (Teva/Active Biotech AB)
4.10.1 Laquinimod: Competitor Analysis and Sales Forecast, 2012-2022
4.11 CXB909 (Krenitsky Pharmaceuticals/CeNeRx BioPharma)
4.11.1 CXB909: Competitor Analysis and Sales Forecast, 2012-2022
5. LEADING ORGANISATIONS IN 2012
5.1 Genervon Biopharmaceuticals
5.1.1 Platforms for Drug Discovery and Development
5.1.2 R&D Pipeline Analysis
5.2 Neuren Pharmaceuticals
5.2.1 Market Position and R&D Pipeline
5.2.2 US Army Funding for NNZ-2566
5.3 NeuroVive Pharmaceutical AB
5.3.1 Current Status and R&D Pipeline
5.3.2 Strategic Collaborations
5.4 Allon Therapeutics
5.4.1 Market Status and R&D Pipeline
5.5 Ceregene
5.5.1 Current Status and R&D Pipeline
5.6 BHR Pharma
5.6.1 Current Status and R&D Pipeline
5.7 Varinel
5.7.1 Current Status and R&D Pipeline
5.7.2 Strategic
Collaborations
5.8 National Institute of Neurological Disorders and Stroke (NINDS)
5.8.1 Research Supported by NINDS
5.9 Leading Countries in Neuroprotective Research
6. NEUROPROTECTIVE AGENTS IN VARIOUS PATHOLOGIES
6.1 Brain Injury
6.1.1 Current Treatment for Brain Injuries
6.1.2 Neuroprotective Agents under Development for Brain Injuries
6.2 Alzheimer's Disease
6.2.1 Limited Number of Drugs Approved for Alzheimer's
6.2.2 Neuroprotective Agents under Development for Alzheimer's Disease
6.3. Parkinson's Disease
6.3.1 Current Therapies for Parkinson's Disease
6.3.2 Neuroprotective Agents under Development for Parkinson's Disease
6.4 Multiple Sclerosis
6.4.1 Current Therapies for Multiple Sclerosis
6.4.2 Neuroprotective Agents under Development for Multiple Sclerosis
6.5 Ocular Degeneration
6.5.1 Current Treatment for Ocular Degeneration
6.5.2 Neuroprotective Agents under Development for Ocular Degeneration
6.6. Other Neurodegenerative Diseases
6.6.1 Huntington's Disease
6.6.1.1 Treatment Options
6.6.2 Amyotrophic Lateral Sclerosis (ALS)
6.6.2.1 Treatment Options
6.6.3 Neuropathies
6.6.3.1 Neuropathic Pain
6.6.3.2 Treatment Options
6.6.4 Neuroprotective Agents under Development for Other Neurodegenerative Diseases
7. NEUROPROTECTIVE AGENTS: QUALITATIVE INDUSTRY ANALYSIS
7.1 Strengths
7.1.1 Neurological Disorders are High Profile
7.1.2 Chronic Diseases: Long-Term Repeat Sale
7.2 Weaknesses
7.2.1 The High Cost of Treatment
7.2.2 Difficulty Generating Ideal Laboratory Models for Neuroprotection
7.2.3 Difficulty in Clinical Trials for Neuroprotection
7.3 Opportunities
7.3.1 Orphan Status and Fast-Track Reviews for New Drugs
7.3.2 Aging Populations Will Lead to Increased Disease Prevalence
7.3.3 Significant Unmet Needs Exist in the Market
7.3.4 Alternative Treatments Provide Additional Opportunities to the Neuroprotection Industry
7.3.4.1 Stem Cell Therapy
7.3.4.2 Gene Therapy
7.4 Threats
8. RESEARCH INTERVIEWS
8.1 Interview with Larry Glass, CEO, Neuren Pharmaceuticals (March 2012)
8.1.1 Failure of Clinical Trials Testing Neuroprotective Agents
8.1.2 Agent NNZ-2566
8.1.3 Sub-classes of Neuroprotective Agent
8.1.4 Promising Neuroprotective Agents
8.1.5 Potential of Neuroprotective Agents
8.2 Interview with Winston Ko, CEO, Genervon Biopharmaceuticals (March 2012)
8.2.1 Lack of Approved Neuroprotective Agents
8.2.2 Sub-classes of Neuroprotective Agent
8.2.3 Agent GM6
8.2.4 Promising Neuroprotective Agents
8.2.5 Potential of Neuroprotective Agents
9. CONCLUSIONS
9.1 High Demand for Neuroprotective Agents in Medicine
9.2 Multibillion Dollar Revenues Possible from World Neuroprotection Market
9.3 Strong R&D Pipeline for Neuroprotective Agents
9.4 Rising Disease Prevalence Levels from Aging Populations Will Drive Market Growth
9.5 Going from Pre-clinical Studies into Clinical Testing Will Remain Challenging
9.6 Concluding Remarks
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Scope of the Report
1.4.1 Inclusions
1.4.2 Exclusions
2. INTRODUCTION TO NEUROPROTECTION
2.1 What is Neuroprotection?
2.2 History of Neuroprotective Agents
2.3 Neurodegeneration
2.3.1 Excitotoxicity
2.3.2 Oxidative Stress
2.4 Mechanisms of Neuroprotection
2.4.1 Ion Channel Modulators
2.4.2 Mitochondrial Dysfunction Regulators
2.4.3 Anti-inflammatory and Anti-apoptotic Agents
2.4.4 Neurotrophic Factors
2.4.5 Other Neuroprotective Agents
2.5 Importance of Neuroprotective Agents
3. WORLD MARKET FOR NEUROPROTECTIVE AGENTS TO 2022
3.1 Neuroprotective Agents: World Market, 2011
3.2 Neuroprotective Agents: World Market Forecast, 2012-2022
3.3 Classes of Neuroprotective Agent
3.3.1 Ion Channel Modulators
3.3.1.1 Ion Channel Modulators: Market Forecast, 2011-2012
3.3.2 Mitochondrial Dysfunction Regulators
3.3.2.1 Mitochondrial Dysfunction Regulators: Market Forecast, 2012-2022
3.3.3 Anti-inflammatory and Anti-apoptotic Agents
3.3.3.1 Anti-inflammatory and Anti-apoptotic Agents: Market Forecast, 2012-2022
3.3.4 Neurotrophic Factors
3.3.4.1 Neurotrophic Factors: Market Forecast, 2012-2022
3.3.5 Other Neuroprotective Agents
3.3.5.1 Other Neuroprotective Agents: Market Forecast, 2012-2022
4. PROMINENT NEUROPROTECTIVE AGENTS UNDER DEVELOPMENT
4.1 Rasagiline (Teva/Lundbeck)
4.1.1 Rasagiline is Currently Approved for Parkinson's Disease
4.1.2 Rasagiline as a Neuroprotectant
4.1.3 Rasagiline: Market Potential Analysis, 2012-2022
4.1.4 Competition for Rasagiline
4.2 Minocycline (National Institute of Neurological Disorders and Stroke [NINDS])
4.2.1 Minocycline: Competitor Analysis and Sales Forecast, 2012-2022
4.3 Memantine (Merz/Lundbeck/Forest Laboratories/Daiichi Sankyo)
4.3.1 Memantine: Competitor Analysis and Sales Forecast, 2012-2022
4.4 NeuroSTAT (NeuroVive Pharmaceutical AB)
4.4.1 NeuroSTAT: Competitor Analysis and Sales Forecast, 2012-2022
4.5 Erythropoietin (Various Companies)
4.5.1 EPO: Competitor Analysis and Sales Forecast, 2012-2022
4.6 GM6 (Genervon Biopharmaceuticals)
4.6.1 Current Status of Development
4.6.2 GM6 Sales Forecast, 2012-2022
4.6.3 GM6: Competitors and Risk Analysis
4.7 NNZ-2566 (Neuren Pharmaceuticals)
4.7.1 NNZ-2566: Competitor Analysis and Sales Forecast, 2012-2022
4.8 Progesterone (BHR-100, BHR Pharma LLC)
4.8.1 Progesterone: Competitor Analysis and Sales Forecast, 2012-2022
4.9 Davunetide (Allon Therapeutics)
4.9.1 Davunetide: Competitor Analysis and Sales Forecast, 2012-2022
4.10 Laquinimod (Teva/Active Biotech AB)
4.10.1 Laquinimod: Competitor Analysis and Sales Forecast, 2012-2022
4.11 CXB909 (Krenitsky Pharmaceuticals/CeNeRx BioPharma)
4.11.1 CXB909: Competitor Analysis and Sales Forecast, 2012-2022
5. LEADING ORGANISATIONS IN 2012
5.1 Genervon Biopharmaceuticals
5.1.1 Platforms for Drug Discovery and Development
5.1.2 R&D Pipeline Analysis
5.2 Neuren Pharmaceuticals
5.2.1 Market Position and R&D Pipeline
5.2.2 US Army Funding for NNZ-2566
5.3 NeuroVive Pharmaceutical AB
5.3.1 Current Status and R&D Pipeline
5.3.2 Strategic Collaborations
5.4 Allon Therapeutics
5.4.1 Market Status and R&D Pipeline
5.5 Ceregene
5.5.1 Current Status and R&D Pipeline
5.6 BHR Pharma
5.6.1 Current Status and R&D Pipeline
5.7 Varinel
5.7.1 Current Status and R&D Pipeline
5.7.2 Strategic
Collaborations
5.8 National Institute of Neurological Disorders and Stroke (NINDS)
5.8.1 Research Supported by NINDS
5.9 Leading Countries in Neuroprotective Research
6. NEUROPROTECTIVE AGENTS IN VARIOUS PATHOLOGIES
6.1 Brain Injury
6.1.1 Current Treatment for Brain Injuries
6.1.2 Neuroprotective Agents under Development for Brain Injuries
6.2 Alzheimer's Disease
6.2.1 Limited Number of Drugs Approved for Alzheimer's
6.2.2 Neuroprotective Agents under Development for Alzheimer's Disease
6.3. Parkinson's Disease
6.3.1 Current Therapies for Parkinson's Disease
6.3.2 Neuroprotective Agents under Development for Parkinson's Disease
6.4 Multiple Sclerosis
6.4.1 Current Therapies for Multiple Sclerosis
6.4.2 Neuroprotective Agents under Development for Multiple Sclerosis
6.5 Ocular Degeneration
6.5.1 Current Treatment for Ocular Degeneration
6.5.2 Neuroprotective Agents under Development for Ocular Degeneration
6.6. Other Neurodegenerative Diseases
6.6.1 Huntington's Disease
6.6.1.1 Treatment Options
6.6.2 Amyotrophic Lateral Sclerosis (ALS)
6.6.2.1 Treatment Options
6.6.3 Neuropathies
6.6.3.1 Neuropathic Pain
6.6.3.2 Treatment Options
6.6.4 Neuroprotective Agents under Development for Other Neurodegenerative Diseases
7. NEUROPROTECTIVE AGENTS: QUALITATIVE INDUSTRY ANALYSIS
7.1 Strengths
7.1.1 Neurological Disorders are High Profile
7.1.2 Chronic Diseases: Long-Term Repeat Sale
7.2 Weaknesses
7.2.1 The High Cost of Treatment
7.2.2 Difficulty Generating Ideal Laboratory Models for Neuroprotection
7.2.3 Difficulty in Clinical Trials for Neuroprotection
7.3 Opportunities
7.3.1 Orphan Status and Fast-Track Reviews for New Drugs
7.3.2 Aging Populations Will Lead to Increased Disease Prevalence
7.3.3 Significant Unmet Needs Exist in the Market
7.3.4 Alternative Treatments Provide Additional Opportunities to the Neuroprotection Industry
7.3.4.1 Stem Cell Therapy
7.3.4.2 Gene Therapy
7.4 Threats
8. RESEARCH INTERVIEWS
8.1 Interview with Larry Glass, CEO, Neuren Pharmaceuticals (March 2012)
8.1.1 Failure of Clinical Trials Testing Neuroprotective Agents
8.1.2 Agent NNZ-2566
8.1.3 Sub-classes of Neuroprotective Agent
8.1.4 Promising Neuroprotective Agents
8.1.5 Potential of Neuroprotective Agents
8.2 Interview with Winston Ko, CEO, Genervon Biopharmaceuticals (March 2012)
8.2.1 Lack of Approved Neuroprotective Agents
8.2.2 Sub-classes of Neuroprotective Agent
8.2.3 Agent GM6
8.2.4 Promising Neuroprotective Agents
8.2.5 Potential of Neuroprotective Agents
9. CONCLUSIONS
9.1 High Demand for Neuroprotective Agents in Medicine
9.2 Multibillion Dollar Revenues Possible from World Neuroprotection Market
9.3 Strong R&D Pipeline for Neuroprotective Agents
9.4 Rising Disease Prevalence Levels from Aging Populations Will Drive Market Growth
9.5 Going from Pre-clinical Studies into Clinical Testing Will Remain Challenging
9.6 Concluding Remarks
LIST OF TABLES
Table 3.1 Neuroprotective Agents: Market Forecast by Drug Categories ($bn), 2011-2022
Table 3.2 Neuroprotective Agents World Market Forecast ($bn), 2011-2022
Table 3.3 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2011
Table 3.4 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2015
Table 3.5 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2022
Table 3.6 Ion Channel Modulators Sales Forecast ($bn), 2011-2022
Table 3.7 Mitochondrial Dysfunction Regulators Sales Forecast ($bn), 2011-2022
Table 3.8 Anti-inflammatory & Anti-apoptotic Agents Forecast ($bn), 2011-2022
Table 3.9 Neurotrophic Factors Forecast ($bn), 2011-2022
Table 3.10 Other Neuroprotective Agents Forecast ($bn), 2011-2022
Table 4.1 Key Neuroprotective Agents: Sales Forecast ($bn), 2011-2022
Table 4.2 Rasagiline Sales Forecast ($bn), 2011-2022
Table 4.3 Studies Investigating Minocycline as a Neuroprotectant
Table 4.4 Minocycline Sales Forecast ($bn), 2011-2022
Table 4.5 Memantine Sales Forecast ($bn), 2011-2022
Table 4.6 NeuroSTAT Sales Forecast ($bn), 2011-2022
Table 4.7 Studies Investigating Erythropoietin as a Neuroprotectant, 2012
Table 4.8 Erythropoietin Sales Forecast ($bn), 2011-2022
Table 4.9 GM6: Preliminary Results, 2012
Table 4.10 GM6 Development, 2012
Table 4.11 GM6 Sales Forecast ($bn), 2011-2022
Table 4.12 NNZ-2566 Sales Forecast ($bn), 2011-2022
Table 4.13 Progesterone Sales Forecast ($bn), 2011-2022
Table 4.14 Davunetide Sales Forecast ($bn), 2011-2022
Table 4.15 Laquinimod Sales Forecast ($bn), 2011-2022
Table 4.16 CXB909 Sales Forecast ($bn), 2011-2022
Table 5.1 Genervon Biopharmaceuticals: R&D Pipeline, 2012
Table 5.2 Neuren Pharmaceuticals: R&D Pipeline, 2012
Table 5.3 NeuroVive Pharmaceutical: R&D Pipeline, 2012
Table 5.4 NeuroVive Pharmaceutical: Strategic Collaborations
Table 5.5 Allon Therapeutics: R&D Pipeline, 2012
Table 5.6 Ceregene: R&D Pipeline, 2012
Table 5.7 BHR Pharma: R&D Pipeline, 2012
Table 5.8 Varinel: R&D Pipeline, 2012
Table 5.9 Varinel: Strategic Collaborations, 2012
Table 5.10 NINDS: Ongoing Clinical Trials, 2012
Table 6.1 Selected Neuroprotective Agents under Investigation for Brain Injury, 2012
Table 6.2 Selected Neuroprotective Agents under Investigation for Alzheimer's Disease, 2012
Table 6.3 Selected Neuroprotective Agents under Investigation for Parkinson's Disease, 2012
Table 6.4 Selected Neuroprotective Agents under Investigation for Multiple Sclerosis, 2012
Table 6.5 Selected Neuroprotective Agents under Investigation for Ocular Degeneration, 2012
Table 6.6 Selected Neuroprotective Agents under Investigation for Other Neurodegenerative Diseases, 2012
Table 7.1 Neuroprotective Agents Market: SWOT Analysis, 2012-2022
Table 7.2 Neuroprotective Agents Market: STEP Analysis, 2012-2022
Table 7.3 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050
Table 9.1 Key Neuroprotective Agents: Sales ($bn) and Market Shares (%), 2022
Table 3.1 Neuroprotective Agents: Market Forecast by Drug Categories ($bn), 2011-2022
Table 3.2 Neuroprotective Agents World Market Forecast ($bn), 2011-2022
Table 3.3 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2011
Table 3.4 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2015
Table 3.5 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2022
Table 3.6 Ion Channel Modulators Sales Forecast ($bn), 2011-2022
Table 3.7 Mitochondrial Dysfunction Regulators Sales Forecast ($bn), 2011-2022
Table 3.8 Anti-inflammatory & Anti-apoptotic Agents Forecast ($bn), 2011-2022
Table 3.9 Neurotrophic Factors Forecast ($bn), 2011-2022
Table 3.10 Other Neuroprotective Agents Forecast ($bn), 2011-2022
Table 4.1 Key Neuroprotective Agents: Sales Forecast ($bn), 2011-2022
Table 4.2 Rasagiline Sales Forecast ($bn), 2011-2022
Table 4.3 Studies Investigating Minocycline as a Neuroprotectant
Table 4.4 Minocycline Sales Forecast ($bn), 2011-2022
Table 4.5 Memantine Sales Forecast ($bn), 2011-2022
Table 4.6 NeuroSTAT Sales Forecast ($bn), 2011-2022
Table 4.7 Studies Investigating Erythropoietin as a Neuroprotectant, 2012
Table 4.8 Erythropoietin Sales Forecast ($bn), 2011-2022
Table 4.9 GM6: Preliminary Results, 2012
Table 4.10 GM6 Development, 2012
Table 4.11 GM6 Sales Forecast ($bn), 2011-2022
Table 4.12 NNZ-2566 Sales Forecast ($bn), 2011-2022
Table 4.13 Progesterone Sales Forecast ($bn), 2011-2022
Table 4.14 Davunetide Sales Forecast ($bn), 2011-2022
Table 4.15 Laquinimod Sales Forecast ($bn), 2011-2022
Table 4.16 CXB909 Sales Forecast ($bn), 2011-2022
Table 5.1 Genervon Biopharmaceuticals: R&D Pipeline, 2012
Table 5.2 Neuren Pharmaceuticals: R&D Pipeline, 2012
Table 5.3 NeuroVive Pharmaceutical: R&D Pipeline, 2012
Table 5.4 NeuroVive Pharmaceutical: Strategic Collaborations
Table 5.5 Allon Therapeutics: R&D Pipeline, 2012
Table 5.6 Ceregene: R&D Pipeline, 2012
Table 5.7 BHR Pharma: R&D Pipeline, 2012
Table 5.8 Varinel: R&D Pipeline, 2012
Table 5.9 Varinel: Strategic Collaborations, 2012
Table 5.10 NINDS: Ongoing Clinical Trials, 2012
Table 6.1 Selected Neuroprotective Agents under Investigation for Brain Injury, 2012
Table 6.2 Selected Neuroprotective Agents under Investigation for Alzheimer's Disease, 2012
Table 6.3 Selected Neuroprotective Agents under Investigation for Parkinson's Disease, 2012
Table 6.4 Selected Neuroprotective Agents under Investigation for Multiple Sclerosis, 2012
Table 6.5 Selected Neuroprotective Agents under Investigation for Ocular Degeneration, 2012
Table 6.6 Selected Neuroprotective Agents under Investigation for Other Neurodegenerative Diseases, 2012
Table 7.1 Neuroprotective Agents Market: SWOT Analysis, 2012-2022
Table 7.2 Neuroprotective Agents Market: STEP Analysis, 2012-2022
Table 7.3 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050
Table 9.1 Key Neuroprotective Agents: Sales ($bn) and Market Shares (%), 2022
LIST OF FIGURES
Figure 3.1 Neuroprotective Agents World Market Forecast ($bn), 2011-2022
Figure 3.2 Neuroprotective Agents Market Shares (%) by Drug Categories, 2011
Figure 3.3 Neuroprotective Agents Market Shares (%) by Drug Categories, 2015
Figure 3.4 Neuroprotective Agents Market Shares (%) by Drug Categories, 2022
Figure 3.5 Ion Channel Modulators Sales Forecast ($bn), 2011-2022
Figure 3.6 Mitochondrial Dysfunction Regulators Sales Forecast ($bn), 2011-2022
Figure 3.7 Anti-inflammatory & Anti-apoptotic Agents Forecast ($bn), 2011-2022
Figure 3.8 Neurotrophic Factors Forecast ($bn), 2011-2022
Figure 3.9 Other Neuroprotective Agents Forecast ($bn), 2011-2022
Figure 4.1 Rasagiline Sales Forecast ($bn), 2011-2022
Figure 4.2 Minocycline Sales Forecast ($bn), 2011-2022
Figure 4.3 Memantine Sales Forecast ($bn), 2011-2022
Figure 4.4 NeuroSTAT Sales Forecast ($bn), 2011-2022
Figure 4.5 Erythropoietin Sales Forecast ($bn), 2011-2022
Figure 4.6 GM6 Sales Forecast ($bn), 2011-2022
Figure 4.7 NNZ-2566 Sales Forecast ($bn), 2011-2022
Figure 4.8 Progesterone Sales Forecast ($bn), 2011-2022
Figure 4.9 Davunetide Sales Forecast ($bn), 2011-2022
Figure 4.10 Laquinimod Sales Forecast ($bn), 2011-2022
Figure 4.11 CXB909 Sales Forecast ($bn), 2011-2022
Figure 7.1 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050
Figure 9.1 Key Neuroprotective Agents: Market Shares (%), 2022
COMPANIES LISTED
Acorda Therapeutics
Active Biotech AB
Advancell
Albert Einstein College of Medicine of Yeshiva University
Alcon Laboratories
Allergan
Allon Therapeutics
Alta Partners
Alzheimer's Drug Discovery Foundation
Alzheimer's Association
Alzheimer's Disease Cooperative Study (ADCS)
American Brain Injury Consortium (ABIC)
Arbor Vita Corporation
Assistance Publique - Häpitaux de Paris
AstraZeneca
Avraham Pharmaceuticals
Bagcilar Training and Research Hospital
Bastyr University
Bayer
Baylor College of Medicine
Besins Healthcare
BHR Pharma
BioAxone Therapeutic
Biogen Idec
BioSante Pharmaceuticals
Brain Cells
BrainStorm Cell Therapeutics
Buck Institute for Research on Aging
Buck Institute of Technology
Buddhist Tzu Chi General Hospital
Cantonal Hospital of St. Gallen
CAS Medical Systems
Catholic University of the Sacred Heart
CeNeRx BioPharma
Centre Hospitalier Universitaire de Nice
Ceregene
Charitй University
CHDI
Children's Hospital & Research Center Oakland
Children's Hospital of Pittsburgh
China Medical University Hospital
Cornell University
Daiichi Sankyo
Danube Pharmaceuticals
DENSMORE Pharmaceutical
Department of Veterans Affairs
Duke University
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Eli Lilly
EMD Serono
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
European Brain Injury Consortium
European Cooperative Network for Research, Diagnosis and Therapy of Parkinson's Disease
Eyetech
Food and Drug Administration (US FDA)
Forest Laboratories
Fundacion para la Investigacion Biomedica del Hospital
Genervon Biopharmaceuticals
GW Pharmaceuticals
Hadassah Medical Organization
Hamilton BioVentures
High Q Foundation
Hoag Memorial Hospital Presbyterian
Huntington Hospital
Huntington Medical Research Institutes
INC Research
Institute for Quality and Efficiency in Health Care (IQWiG)
Investor Growth Capital
Janssen
Jaslok Hospital and Research Centre
Krenitsky Pharmaceuticals
Laerdal Medical
Lundbeck
Max Planck Institute
Medical University of South Carolina
Merz Pharmaceuticals
Michael J. Fox Foundation for Parkinson's Research
Mount Sinai School of Medicine
MPM Capital
Multiple Sclerosis Society of Great Britain and Northern Ireland
Multiple Sclerosis Trust
Mylan
National Center for Complementary and Alternative Medicine (NCCAM)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute for Health and Clinical Excellence (NICE)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
National Institutes of Health Clinical Center (CC)
National Multiple Sclerosis Society
Neuralstem
Neuregenix
Neuren Pharmaceuticals
Neurological Emergencies Treatment Trials Network (NETT)
Neuroscience Canada
Neurotec Pharma
Neurotech
NeuroVive Pharmaceutical AB
Newron Pharmaceuticals
NoNO
Northwestern University
Novartis
Office of Dietary Supplements (ODS)
Ono Pharmaceutical
Opexa Therapeutics
Oregon Health and Science University
Orion Pharma
Oxygen Biotherapeutics
Pfizer
Pharmanza Herbal
PRA International
Prana Biotechnology
QLT
Quark Pharmaceuticals
Rexahn Pharmaceuticals
Roche
Royan Institute
Rush University Medical Center
S & T Global
Sanofi
Santa Clara Valley Health & Hospital System
Selcia
Shaheed Beheshti Medical University
SK Biopharmaceuticals
StoneBridge Pharma
TCA Cellular Therapy
Technion Medical School
Teva Pharmaceutical Industries
Texas Children's Hospital
The Dana Foundation
Thrasher Research Fund
to-BBB
Toyama Chemical Co.
Universitaria Meyer
Universitaria Pisana
Universitario Ramon y Cajal
University College London
University of Calgary
University of California, Los Angeles
University of California, San Francisco
University of Miami
University of Rochester
University of South Florida
University of Utah
University of Washington
Varinel
Verdure Sciences
U.S. Department of Defense
Watson Pharmaceuticals
World Health Organization (WHO)
Xuanwu Hospital, Beijing
Zambon Company
Figure 3.1 Neuroprotective Agents World Market Forecast ($bn), 2011-2022
Figure 3.2 Neuroprotective Agents Market Shares (%) by Drug Categories, 2011
Figure 3.3 Neuroprotective Agents Market Shares (%) by Drug Categories, 2015
Figure 3.4 Neuroprotective Agents Market Shares (%) by Drug Categories, 2022
Figure 3.5 Ion Channel Modulators Sales Forecast ($bn), 2011-2022
Figure 3.6 Mitochondrial Dysfunction Regulators Sales Forecast ($bn), 2011-2022
Figure 3.7 Anti-inflammatory & Anti-apoptotic Agents Forecast ($bn), 2011-2022
Figure 3.8 Neurotrophic Factors Forecast ($bn), 2011-2022
Figure 3.9 Other Neuroprotective Agents Forecast ($bn), 2011-2022
Figure 4.1 Rasagiline Sales Forecast ($bn), 2011-2022
Figure 4.2 Minocycline Sales Forecast ($bn), 2011-2022
Figure 4.3 Memantine Sales Forecast ($bn), 2011-2022
Figure 4.4 NeuroSTAT Sales Forecast ($bn), 2011-2022
Figure 4.5 Erythropoietin Sales Forecast ($bn), 2011-2022
Figure 4.6 GM6 Sales Forecast ($bn), 2011-2022
Figure 4.7 NNZ-2566 Sales Forecast ($bn), 2011-2022
Figure 4.8 Progesterone Sales Forecast ($bn), 2011-2022
Figure 4.9 Davunetide Sales Forecast ($bn), 2011-2022
Figure 4.10 Laquinimod Sales Forecast ($bn), 2011-2022
Figure 4.11 CXB909 Sales Forecast ($bn), 2011-2022
Figure 7.1 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050
Figure 9.1 Key Neuroprotective Agents: Market Shares (%), 2022
COMPANIES LISTED
Acorda Therapeutics
Active Biotech AB
Advancell
Albert Einstein College of Medicine of Yeshiva University
Alcon Laboratories
Allergan
Allon Therapeutics
Alta Partners
Alzheimer's Drug Discovery Foundation
Alzheimer's Association
Alzheimer's Disease Cooperative Study (ADCS)
American Brain Injury Consortium (ABIC)
Arbor Vita Corporation
Assistance Publique - Häpitaux de Paris
AstraZeneca
Avraham Pharmaceuticals
Bagcilar Training and Research Hospital
Bastyr University
Bayer
Baylor College of Medicine
Besins Healthcare
BHR Pharma
BioAxone Therapeutic
Biogen Idec
BioSante Pharmaceuticals
Brain Cells
BrainStorm Cell Therapeutics
Buck Institute for Research on Aging
Buck Institute of Technology
Buddhist Tzu Chi General Hospital
Cantonal Hospital of St. Gallen
CAS Medical Systems
Catholic University of the Sacred Heart
CeNeRx BioPharma
Centre Hospitalier Universitaire de Nice
Ceregene
Charitй University
CHDI
Children's Hospital & Research Center Oakland
Children's Hospital of Pittsburgh
China Medical University Hospital
Cornell University
Daiichi Sankyo
Danube Pharmaceuticals
DENSMORE Pharmaceutical
Department of Veterans Affairs
Duke University
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Eli Lilly
EMD Serono
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
European Brain Injury Consortium
European Cooperative Network for Research, Diagnosis and Therapy of Parkinson's Disease
Eyetech
Food and Drug Administration (US FDA)
Forest Laboratories
Fundacion para la Investigacion Biomedica del Hospital
Genervon Biopharmaceuticals
GW Pharmaceuticals
Hadassah Medical Organization
Hamilton BioVentures
High Q Foundation
Hoag Memorial Hospital Presbyterian
Huntington Hospital
Huntington Medical Research Institutes
INC Research
Institute for Quality and Efficiency in Health Care (IQWiG)
Investor Growth Capital
Janssen
Jaslok Hospital and Research Centre
Krenitsky Pharmaceuticals
Laerdal Medical
Lundbeck
Max Planck Institute
Medical University of South Carolina
Merz Pharmaceuticals
Michael J. Fox Foundation for Parkinson's Research
Mount Sinai School of Medicine
MPM Capital
Multiple Sclerosis Society of Great Britain and Northern Ireland
Multiple Sclerosis Trust
Mylan
National Center for Complementary and Alternative Medicine (NCCAM)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute for Health and Clinical Excellence (NICE)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
National Institutes of Health Clinical Center (CC)
National Multiple Sclerosis Society
Neuralstem
Neuregenix
Neuren Pharmaceuticals
Neurological Emergencies Treatment Trials Network (NETT)
Neuroscience Canada
Neurotec Pharma
Neurotech
NeuroVive Pharmaceutical AB
Newron Pharmaceuticals
NoNO
Northwestern University
Novartis
Office of Dietary Supplements (ODS)
Ono Pharmaceutical
Opexa Therapeutics
Oregon Health and Science University
Orion Pharma
Oxygen Biotherapeutics
Pfizer
Pharmanza Herbal
PRA International
Prana Biotechnology
QLT
Quark Pharmaceuticals
Rexahn Pharmaceuticals
Roche
Royan Institute
Rush University Medical Center
S & T Global
Sanofi
Santa Clara Valley Health & Hospital System
Selcia
Shaheed Beheshti Medical University
SK Biopharmaceuticals
StoneBridge Pharma
TCA Cellular Therapy
Technion Medical School
Teva Pharmaceutical Industries
Texas Children's Hospital
The Dana Foundation
Thrasher Research Fund
to-BBB
Toyama Chemical Co.
Universitaria Meyer
Universitaria Pisana
Universitario Ramon y Cajal
University College London
University of Calgary
University of California, Los Angeles
University of California, San Francisco
University of Miami
University of Rochester
University of South Florida
University of Utah
University of Washington
Varinel
Verdure Sciences
U.S. Department of Defense
Watson Pharmaceuticals
World Health Organization (WHO)
Xuanwu Hospital, Beijing
Zambon Company
